8.41 0.00 (0.00%)
After hours: 4:17PM EDT
|Bid||8.32 x 1000|
|Ask||8.45 x 1300|
|Day's Range||8.36 - 8.75|
|52 Week Range||8.33 - 27.45|
|Beta (3Y Monthly)||1.05|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 5, 2019 - Aug 9, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||27.50|
Myovant's plan to control heavy menstrual bleeding, how President Trump's executive order on kidney treatments could help a San Francisco company and more in our Health Care Digest.
Myovant Sciences (NYSE: MYOV), a healthcare company focused on developing innovative treatments for women's health and prostate cancer, and Evidation Health, a health and measurement company that helps life sciences and healthcare companies understand how everyday behavior and health interact, today announced a collaboration to conduct a digital study on the prevalence and impact of menstrual symptoms experienced by women in the U.S., as well as an evaluation of the education and attitudes of women and men regarding menstruation. The digital study launched today involves over 20,000 people, who will receive survey questions via Evidation’s health app, Achievement, which engages with a population of over 3 million people across the U.S..
Actions speak louder than words, as the saying goes. And when it comes to insiders, that certainly seems to be the case. If we track informative insider buy transactions, we can get an idea of the stocks that insiders see as compelling investing opportunities right now. As insiders have access to a wealth of company information, these insights can be very valuable when deciding which stocks to buy or sell. With that in mind we took a closer look at three stocks insiders are snapping up right now: Immunomedics (IMMU)Immunomedics focuses on the development of antibody-drugs for the treatment of cancer. Most notably sacituzumab has received Breakthrough Therapy designation from the FDA for the treatment of patients with triple-negative breast cancer (TNBC) who failed previous therapies. It’s also granted the drug fast track designation for lung cancer treatment. Shares have surged 12% in the last five days, and that’s partly down to an influx of insider money. Most notably, corporate director and owner venBio Select Advisor LLC recently picked up a whopping $13.5 million worth of stock. That brings venBio’s total holding of IMMU to just over $298 million. And it’s not just insiders that are bullish. The stock also shows a ‘Strong Buy’ analyst consensus with an average price target of $23- indicating that further upside potential of 54% lies ahead. “As we expect sacituzumab to address a major unmet need in the treatment of r/r mTNBC [metastatic triple negative breast cancer] next year, we continue to think that IMMU is undervalued for its potential” comments Cowen & Co analyst Phil Nadeau. “We continue to expect sacituzumab will become a standard mTNBC treatment upon its approval” the analyst added. He notes that Daiichi’s DS-1062a has the potential to be long-term competition to IMMU's sacituzumab- but reassures investors that IMMU is clearly well ahead. “Given sacituzumab's several-year lead, it will be incumbent upon DS-1062a to show meaningful advantages in order to displace it” the analyst writes. Fastly Inc (FSLY)Cloud computing services provider Fastly is a newcomer to the markets. The company, which helps companies deliver online content more quickly, debuted on the NYSE back in May. Its IPO was a great success; the company sold 11.25 million shares at $16 each, bringing returns of $180 million. Since the IPO shares have surged to the current price of $20.55.And now we can see that insiders are already pouring more money into this fast-growing tech stock. Abdiel Capital Management, one of the company’s owners, has just picked up a further $7.62 million of FSLY stock. This brings the total holding to $78.8 million. No doubt this move would make sense to five-star analyst Brad Reback of Stifel Nicolaus. He initiated coverage of the stock with a buy rating and $25 price target (22% upside potential). The analyst contends: “In the coming years, we believe Fastly can leverage its superior technological approach to drive continued strong net new customer additions and expand its wallet share among its existing installed base.” Combined with a large market opportunity and the ability to further penetrate international markets, Reback is confident that Fastly can sustain at least a 30% top-line growth profile. Myovant Sciences (MYOV)Myovant Sciences is a clinical-stage biopharma developing therapies for women’s health and endocrine diseases. Shares have crashed 47% year-to-date, with the selloff prompted by the release of relugolix phase 3 uterine fibroids data. Investors are concerned about Abbvie’s (ABBV) uterine fibroid rival, Orlissa.However, insiders are demonstrating their confidence in the company. In the last three months insiders have bought a whopping $160 million of shares. That includes a $45,000 purchase from director Sebelius Kathleen, as well as $20 million from owner Viking Global Investors. Indeed, all ten transactions in the last month are positive insider buy transactions- with only one insider sell transaction recorded four months ago.Furthermore, the Street is also staying onside. All five analysts covering the stock rate Myovant a ‘buy.’ That gives the stock its ‘Strong Buy’ analyst consensus. Meanwhile their average price target of $26 indicates massive upside potential of 194%. Analysts argue that the stock looks oversold at current levels, with Barclays analyst Geoffrey Meacham saying he still believes Myovant’s relugolix has a favorable profile compared to rival offerings. Meanwhile five-star Evercore ISI analyst Ravi Mehrotra is anticipating revenues of $944M for relugolix by 2023 due to its "commercial advantage of a one-a-day pill." Discover more Hot Insider Trading Stocks here
A live webcast of each event will be accessible on the Events page under the Investors and Media section of the Myovant website at www.myovant.com. Myovant Sciences is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of women's health and endocrine diseases.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 30) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Misonix, ...
Myovant Sciences (MYOV) (“Myovant”), a clinical-stage healthcare company focused on developing and commercializing innovative therapies for women’s health and prostate cancer, today announced the pricing of its underwritten public offering of 15,151,516 of its common shares at a price to the public of $8.25 per share. All of the common shares are being offered by Myovant. In connection with this offering, Myovant has granted the underwriters a 30-day option to purchase up to an additional 2,272,727 of its common shares on the same terms and conditions. The offering is expected to close on June 4, 2019, subject to the satisfaction of customary closing conditions.
Myovant Sciences (MYOV) (“Myovant”), a clinical-stage healthcare company focused on developing and commercializing innovative therapies for women’s health and prostate cancer, today announced that it has commenced an underwritten public offering of $100 million of its common shares. All of the common shares are being offered by Myovant. In connection with this offering, Myovant expects to grant the underwriters a 30-day option to purchase up to an additional $15.0 million of its common shares in the offering on the same terms and conditions.
-Announced positive Phase 3 results from LIBERTY 1 study evaluating relugolix combination therapy in women with uterine fibroids- -Data from four additional Phase 3 clinical.
Bay Area companies are gearing up for ASCO, HCP's Brisbane biotech building is on the rise and more in our Health Care Digest.
Myovant released topline data from one of the Phase 3 studies, dubbed LIBERTY 1, which evaluated the drug relugolix. The data showed that the study met its primary efficacy endpoint, with 73.4 percent of women receiving the combo therapy achieving a menstrual blood loss volume of less than 80 ml compared to 18.9 percent for placebo. Relugolix, an oral once-daily small molecule acting as a gonadotropin-releasing hormone, is being tested in a 40mg dose in combination with 1mg estradiol and 0.5mg norethindrone acetate.
Shares of Myovant Sciences rose 1.6% in premarket trade Tuesday after the company announced a late-stage study of a uterine fibroid treatment met its primary endpoint and several secondary endpoints. The Phase 3 trial showed that a greater proportion (73.4%) of women on a once-daily combination therapy of the drug showed significant improvement in blood loss than those on placebo (18.9%). Bone density levels in women on the therapy were also comparable to that of those on placebo, and those on the drug experienced on average an 84.3% reduction in menstrual blood loss from baseline, the company said. Relugolix is a once-daily oral drug that blocks receptors for a hormone called gonadotropin-releasing hormone. That reduces the ovaries' production of estradiol, a hormone that stimulates uterine fibroid growth. Myovant shares have gained 5% in the year to date, while the S&P 500 has gained 12%.
Myovant Sciences Ltd said on Tuesday its combination therapy met the main goal of a late-stage study testing the treatment in women with uterine fibroids. The company said 73.4% of women receiving the once-daily treatment showed a greater reduction in menstrual blood loss compared with 18.9% of women receiving placebo. Uterine fibroids are non-cancerous tumors that develop in or on the muscular walls of the uterus and are among the most common reproductive tract tumors, affecting about 5 million women in the United States.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...
Myovant Sciences (MYOV), a clinical-stage healthcare company focused on developing and commercializing innovative therapies for women’s health and prostate cancer, today announced that LIBERTY 1, the first of two Phase 3 studies of once daily relugolix combination therapy met its primary efficacy endpoint and six key secondary endpoints in women with uterine fibroids. Relugolix combination therapy maintained bone mineral density at levels comparable to placebo over 24 weeks and was generally well tolerated.
BASEL, Switzerland, May 13, 2019 -- Myovant Sciences (NYSE:MYOV), a clinical-stage healthcare company focused on developing and commercializing innovative therapies for women’s.
Hedge funds are not perfect. They have their bad picks just like everyone else. Facebook, a stock hedge funds have loved, lost nearly 40% of its value at one point in 2018. Although hedge funds are not perfect, their consensus picks do deliver solid returns, however. Our data show the top 15 S&P 500 stocks […]
BASEL, Switzerland , March 5, 2019 /PRNewswire/ -- Myovant Sciences (NYSE: MYOV ), a leading clinical-stage biopharmaceutical company focused on women's health and endocrine diseases, today announced ...
In our view, Myovant (MYOV) is poised for significant value creation in the next 6-12 months, explains John McCamant, biotechnology specialist and editor of The Medical Technology Stock Letter.
The Hamilton, Bermuda-based company said it had a loss of $1.04 per share. The results missed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was ...
- Top-line results for LIBERTY 1 and LIBERTY 2 Phase 3 trials in uterine fibroids as well as HERO Phase 3 trial in prostate cancer expected in Q2, Q3 and Q4 2019, respectively - BASEL, Switzerland , Feb. ...
- In addition to Roivant, four Vants will be presenting at JPM this year NEW YORK and BASEL, Switzerland , Jan. 2, 2019 /PRNewswire/ -- Roivant Sciences today announced that Vivek Ramaswamy , Founder and ...